|
× |
 |
Ziprasidone in Treatment-Resistant Schizophrenia: A 52-Week, Open-Label Continuation Study PDF |
$40.00 |
|
$40.00 |
|
× |
|
Vaccine-Induced Psychosis as an Etiology to Consider in the Age of COVID-19 PDF |
$40.00 |
|
$40.00 |
|
× |
|
The Clinician’s Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia PDF |
$40.00 |
|
$40.00 |
|
× |
|
Effectiveness and Tolerability of Supratherapeutic Dosing of Vortioxetine in Patients With Treatment-Resistant Depression PDF |
$40.00 |
|
$40.00 |
|
× |
|
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. PDF |
$40.00 |
|
$40.00 |
|
|
